Neumora Therapeutics

NSQ:NMRA · US6409791000

PharmaceuticalsSmall

360° View

Value81

Price/Sales—

Price/Earnings50

Price/Book93

Dividend Yield1

Growth49

Revenue Growth—

Profit Growth15

Capital Growth63

TSR 52w72

Safety19

Leverage39

Liquidity12

Refinancing22

Combined30

Sentiment39

Analyst Opinions27

Pro Holdings33

Opinion Changes50

Market Pulse65

Profile

CountryUSA

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2019

Employees87

Websiteneumoratx.com

ISINUS6409791000

Last UpdateApr 2, 2026

Index & Theme

NeurologyNeurosciencePsychiatryCentral Nervous SystemGeneticsBiotechnologyHealth CareMedical

Description

Neumora Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company engages in the development of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neurop…

Analysis

Neumora Therapeutics's 360° View rank of 9 places it among the weakest overall — better than 9% of its true peers.

It's growing slowly (49) and looks cheap versus peers (81). On safety it is highly leveraged (19), and the market shows muted sentiment (39). Taken together, its Combined rank of 30 reads as below its peer average.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Neumora Therapeutics with its peers

Omeros

NMQ:OMER

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

LB Pharmaceuticals

NMQ:LBRX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Ocular Therapeutix

NMQ:OCUL

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

EyePoint

NMQ:EYPT

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Insmed

NSQ:INSM

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

MIRA Pharmaceuticals

NAQ:MIRA

—

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →